US Patent 7,381,560: anti-CD20 chimeric Ig sequence claims and the U.S. patent landscape

What does US 7,381,560 claim, in claim-structure terms?

US 7,381,560 claims (i) a host cell engineered with specific nucleic acid segments that encode defined portions of a chimeric anti-CD20 antibody, and (ii) methods of expressing and purifying the antibody from that host cell.

Claim 1: the core infringement hook (defined human/chimeric fragment ranges)

Claim 1 requires a host cell with:

Light chain expression cassette
Nucleic acid encoding amino acid residues 23 to 128 of SEQ ID NO: 4.
Heavy chain expression cassette
Nucleic acid encoding amino acid residues 20 to 140 of SEQ ID NO: 6.
Functional requirement
The host cell can express and secrete an “immunologically active chimeric anti-CD20 antibody.”

This is a classic “sequence-fragment to functional antibody” claim. The legal boundary is tightest at the fragment definition: infringement depends on whether the expressed light and heavy chains correspond to the claimed residue ranges of the specified SEQ ID NOs, not merely on target binding to CD20.

Claims 2 and 3: constant-region and end-to-end production

Claim 2 adds specific constant regions:
- Light chain includes a human kappa constant region.
- Heavy chain includes a human gamma 1 (IgG1) constant region.
Claim 3 adds the production method:
- Express the light and heavy chains encoded by the claim 1 nucleic acids in the claim 1 host cell.
- Purify the antibody produced.

Claims 4 and 5: formulation buffer/carrier variants

Claim 4: combine purified antibody with a pharmaceutically acceptable buffer.
Claim 5: combine purified antibody with a pharmaceutical carrier.

These are broad “finishing step” claims that usually do not add much patentability relative to the core antibody-expressing step, but they expand the method claim’s coverage to downstream formulation activities.

Claims 6 to 10: expression vector and host-cell genus/species

These claims narrow or diversify the manufacturing setup:

Claim 6: host cell comprises an expression vector (or separate vectors).
Claim 7: host cell comprises expression plasmid(s) (or separate plasmid(s)).
Claim 8: host cell is mammalian.
Claims 9 and 10: host cell is specifically CHO and SP2/0.

From a landscape perspective, claims 8 to 10 matter because many competing products and process patents use CHO or myeloma lines as expression platforms. Claim coverage will hinge on whether the engineered constructs express the same defined fragment sequences as SEQ IDs within the claimed residue ranges.

How strong are these claims against common anti-CD20 biosimilar/process designs?

The enforceability and practical “workability” of the claims depend on whether competitors can:

1) Avoid expressing the same light and heavy chain residue segments as those tied to SEQ ID NO: 4 and SEQ ID NO: 6, and
2) Avoid the human kappa and human IgG1 constant-region configuration (claim 2) if they fall under that dependent claim.

Key technical leverage point: residue-range plus SEQ ID linkage

The claims are not a generic “anti-CD20 chimeric antibody.” They map to particular parts of antibody sequences (residue ranges) with a direct tie to SEQ IDs.

If an alternative anti-CD20 chimeric antibody uses different V-region boundaries, different engineered junctions, or different CDR framing, it may avoid literal infringement even if it binds CD20.
If the competitor uses the same variable region architecture but changes constant region class (for example, gamma 4 instead of gamma 1), it can potentially avoid claim 2 while still falling within claim 1 depending on how the constant region is embedded in the claimed heavy-chain residue range and the SEQ ID mapping.

Production platform carve-outs are limited

Claim 8 does not broaden beyond mammalian cells; claims 9 and 10 specifically include CHO and SP2/0. If a competitor uses these platforms, it does not avoid infringement by platform choice alone. Avoidance requires sequence and expression-cassette differences, not merely choosing a different mammalian host.

“Purification + buffer/carrier” are likely broad and not limiting

Claims 3 to 5 are manufacturing steps that generally track standard biologics production workflows. They rarely limit scope enough to avoid core sequence infringement, because purification and formulation are default end-stage operations. The meaningful narrowing for competitors is the antibody sequence requirement from claim 1 and constant region configuration from claim 2.

What is the likely intended antibody identity behind SEQ IDs?

Without the patent text showing the full sequences, the landscape inference is constrained. The claims’ structure strongly indicates the patent is aimed at a specific chimeric anti-CD20 antibody with:

light chain featuring human kappa constant region,
heavy chain featuring human IgG1 constant region,
variable-region boundaries defined by residues 23-128 (light) and 20-140 (heavy) mapped to SEQ IDs.

In practical terms, the target is likely a hybrid of rodent monoclonal variable regions joined to human constant regions (a typical chimeric IgG construction). For infringement design-around, competitors will focus on whether their sequences match these defined residue ranges and whether the SEQ IDs encode the same variable domain implementations.

Critical evaluation: where these claims sit in the patent landscape risk map

1) Claim scope is narrower than “any anti-CD20 antibody,” but broader than “one patent family member”

Narrower because it requires precise SEQ ID-driven residue ranges.
Broader because once the sequence requirement is met, the host cell can use generic mammalian expression vectors/plasmids and CHO or SP2/0 are explicitly in-scope.
The method claims also cover standard purification and formulation steps.

2) The claims are “single-target” and “manufacturing-enabled,” which tends to raise enforcement utility

Infringement theories in this kind of patent usually proceed through:

possession or use of host cell constructs that express the claimed antibody, and
manufacture/purification steps that produce the antibody for sale or clinical use.

This can be actionable without proving a specific clinical formulation, because claim 3 already covers purified antibody production, while claims 4 and 5 cover buffer/carrier variants.

3) The landscape risk shifts from clinical to sequence and process documentation

For investors and R&D teams, this means clearance focuses on:

the exact expressed light and heavy chain sequences in the final product cell line,
construct maps and junction sequences used to generate those domains,
constant region class and any engineered substitutions.

A competitor can often maintain CD20 binding and still avoid infringement by changing the variable-region sequences so that the expressed residues no longer match the claimed residue ranges tied to the SEQ IDs.

How to read US 7,381,560 against typical anti-CD20 biosimilar strategies

Biosimilar strategy: often keeps binding but changes manufacturing and sometimes sequence

Most biosimilar and follow-on biologic strategies preserve:

target binding and epitope class,
Fc properties within reason for effector function, and
product manufacturability.

The patent’s sequence-specific fragment language can be incompatible with “easy” biosimilar reengineering if the biosimilar’s expressed domains differ at any residue in the claimed ranges or if their SEQ ID mapping does not align.

Process strategy alone is not a safe design-around

Switching:

cell line from CHO to another mammal,
promoter/enhancer,
vector backbone, or
purification chromatography train, does not avoid a claim that is anchored on expressed antibody sequence fragments.

Constant region is a potential escape hatch, but only if it breaks claim 2 cleanly

Claim 2 is specific: human kappa + human gamma 1. A competitor that uses a different heavy constant region class (not gamma 1) could avoid claim 2. But whether claim 2 is the only obstacle depends on how the heavy-chain residue range of claim 1 maps onto the heavy constant region in the SEQ ID.

Patent landscape implications (what matters to watch in related U.S. filings)

Given the lack of provided bibliographic data in the prompt (filing date, priority, assignees, and family members), the only defensible “landscape” content is structural: where similar claims tend to cluster.

In anti-CD20 biologics, U.S. IP landscape typically divides across: 1) Antibody sequence and variable-region composition (composition-of-matter, binding, and functional variants), 2) Expression systems and production methods (host cell lines, plasmid constructs), 3) Formulation and delivery (buffer/carrier, lyophilized vs liquid, device delivery), 4) Downstream purification and quality control (not usually this patent’s focus given the broad purification steps in claim 3).

US 7,381,560 concentrates the most enforceable hooks in (1) and (2) because claim 1 is sequence-fragment-defined and claim 3 ties it to actual expression and purification.

Investor/R&D takeaway: if your candidate uses a chimeric anti-CD20 IgG1 with variable domains that match the SEQ IDs and residue boundaries, you face high risk even if you use a different CHO clone, different vector, or different purification. If variable domains differ, risk can drop substantially because claims 1 and 2 are sequence-anchored.

Claim-by-claim risk scoring (practical)

Risk to competitors that express the claimed antibody exactly: high.
Risk to competitors that bind CD20 but differ in variable-region sequence: low to moderate depending on exact residue identity.

Claim	What must be true for infringement	Main design-around lever
1	Host cell expresses/secretes chimeric anti-CD20 with light residues 23-128 (SEQ ID 4) and heavy residues 20-140 (SEQ ID 6)	Change variable-region sequence so expressed residues no longer match SEQ ID residue ranges
2	Claim 1 plus human kappa constant and human gamma 1 constant	Use non-kappa or non-gamma1 constant implementation, if it changes the relevant mapped residues
3	Claim 1 plus express and purify antibody	Avoid the specific claim 1 antibody expression; process changes alone are insufficient
4	Claim 3 plus buffer formulation	Not a real escape from sequence infringement
5	Claim 3 plus pharmaceutical carrier formulation	Not a real escape from sequence infringement
6	Claim 1 plus vector(s) containing sequences	Not a real escape if sequences match
7	Claim 1 plus plasmid(s) containing sequences	Not a real escape if sequences match
8	Claim 1 plus mammalian host	Not a real escape if CHO/SP2/0 or other mammalian expression is still used
9	Claim 1 plus CHO	Not a real escape if CHO expresses the claimed sequences
10	Claim 1 plus SP2/0	Not a real escape if SP2/0 expresses the claimed sequences

Key Takeaways

US 7,381,560 is anchored on sequence-defined antibody fragments: light chain residues 23-128 of SEQ ID NO: 4 and heavy chain residues 20-140 of SEQ ID NO: 6. CD20 binding alone is not the claim; the expressed sequence fragments are.
Dependent claim 2 adds human kappa and human IgG1 gamma 1 constant regions, which can be an additional sequence-architecture constraint.
Method and formulation claims (3-5) are broad and generally do not create meaningful design-around routes if the antibody sequence is the same.
CHO and SP2/0 host-cell specificity (9-10) means platform substitution is not a reliable workaround; avoiding infringement requires construct sequence differences that break the SEQ ID/residue-range mapping.

FAQs

1) Does claim 1 cover any anti-CD20 antibody that binds CD20?
No. It covers a host cell that expresses a chimeric anti-CD20 antibody with the specific light and heavy chain residue ranges tied to SEQ ID NO: 4 and SEQ ID NO: 6.

2) Is using CHO or SP2/0 alone enough to infringe?
No. CHO/SP2/0 are specified in dependent claims, but infringement still requires expression of the antibody that matches the SEQ ID/residue-range requirements.

3) Can a different purification process avoid claim 3?
No. Claim 3 requires expressing and purifying the antibody from the claim 1 host cell. Changing chromatography typically does not avoid infringement if the same antibody is produced.

4) What is the most practical design-around lever?
Changing the variable-region sequence boundaries and residues so the expressed light/heavy chains do not match the claimed residue ranges of the specified SEQ IDs.

5) Do claims 4 and 5 meaningfully narrow the scope?
They add formulation steps (buffer/carrier) but usually do not overcome the core limitation that the host cell must express the claimed chimeric anti-CD20 antibody.

References

1) United States Patent 7,381,560, claims 1-10 (as provided in the prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	February 19, 2002	7,381,560	2021-07-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	938466	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9411026	⤷ Start Trial
United States of America	7744877	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 7,381,560

Summary for Patent: 7,381,560